MCID: TRY001
MIFTS: 53

Trypanosomiasis

Categories: Infectious diseases

Aliases & Classifications for Trypanosomiasis

MalaCards integrated aliases for Trypanosomiasis:

Name: Trypanosomiasis 12 55 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:10113
ICD10 33 B57.2
ICD9CM 35 086 086.9
MeSH 44 D014352
SNOMED-CT 68 78940002
UMLS 73 C0041227

Summaries for Trypanosomiasis

Disease Ontology : 12 A parasitic protozoa infectious disease that involves infection caused by parasitic protozoan of the genus Trypanosoma in animals and humans.

MalaCards based summary : Trypanosomiasis is related to sleeping sickness and chagas disease. An important gene associated with Trypanosomiasis is APOL1 (Apolipoprotein L1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Enalapril and Enalaprilat have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and t cells, and related phenotypes are Reduced mammosphere formation and cellular

Wikipedia : 76 Trypanosomiasis or trypanosomosis is the name of several diseases in vertebrates caused by parasitic... more...

Related Diseases for Trypanosomiasis

Diseases related to Trypanosomiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 415)
# Related Disease Score Top Affiliating Genes
1 sleeping sickness 33.4 TF ODC1 IL6 IL10 HPR HP
2 chagas disease 32.5 TNF TLR2 IL6 IL1B IL10 IFNG
3 leishmaniasis 30.4 TNF TLR9 TLR2 IL6 IL4 IL1B
4 glomerulonephritis 30.2 ALB CCL2 IL1B TLR9
5 transverse myelitis 30.1 CXCL8 IL10 IL6 TNF
6 endomyocardial fibrosis 30.1 IL10 IL4 TNF
7 filarial elephantiasis 30.0 IL10 IL4 TLR2 TLR9
8 schistosomiasis 30.0 ALB CCL3 IFNG IL10 IL4 TNF
9 anterior uveitis 30.0 IL6 TLR2 TNF
10 toxoplasmosis 29.9 TNF TLR9 TLR2 IL6 IL4 IL1B
11 uveitis 29.9 CCL2 IFNG IL10 IL4 TNF
12 filariasis 29.8 TNF TLR9 TLR2 IL6 IL10 IFNG
13 brucellosis 29.8 CXCL8 IFNG IL10 IL4 IL6 TNF
14 acquired immunodeficiency syndrome 29.7 ALB CCL3 IFNG IL10 IL1B IL6
15 human immunodeficiency virus infectious disease 29.7 CCL3 IFNG IL10 IL6 TLR9 TNF
16 cutaneous leishmaniasis 29.6 IFNG IL10 IL4 TLR2 TLR9 TNF
17 visceral leishmaniasis 29.6 TNF TLR9 TLR2 IL4 IL10 IFNG
18 malaria 29.3 TNF TLR9 TLR2 TF IL6 IL4
19 viral infectious disease 29.2 TNF TLR9 IL6 IL4 IL1B IL10
20 trypanosomiasis, human east-african 12.4
21 trypanosomiasis, human west-african 12.0
22 eastern equine encephalitis 11.1
23 punctate inner choroidopathy 10.4 IL10 TNF
24 scorpion envenomation 10.3 IL6 TNF
25 cephalosporin allergy 10.3 IFNG IL10
26 staphylococcal toxic shock syndrome 10.3 IFNG IL1B TNF
27 eye lymphoma 10.3 IL10 IL6 TLR9
28 trachoma 10.3 IDO1 IL10 TNF
29 mucocutaneous leishmaniasis 10.3 IL10 TLR9 TNF
30 chronic active epstein-barr virus infection 10.3 IDO1 IFNG IL10
31 spotted fever 10.3 IFNG IL10 TNF
32 hand, foot and mouth disease 10.3 IFNG IL10 IL6
33 post-transplant lymphoproliferative disease 10.3 IL10 IL6 TNF
34 fungal meningitis 10.3 CCL2 IFNG IL10
35 posterior uveitis 10.3 IFNG IL6 TNF
36 trichuriasis 10.3 CXCL8 IL10 TNF
37 acute transverse myelitis 10.3 CXCL8 IL10 IL6
38 glossitis 10.3 IL1B IL6 TNF
39 laryngitis 10.3 IL1B IL6 TNF
40 cardiac sarcoidosis 10.3 CXCL8 IFNG TNF
41 exudative glomerulonephritis 10.3 CXCL8 IL1B TNF
42 streptococcal toxic-shock syndrome 10.3 CXCL8 IL6 TNF
43 acute vascular insufficiency of intestine 10.3 IL1B IL6 TNF
44 leukomalacia 10.3 IL6 TNF
45 listeriosis 10.3 IDO1 IL6 TNF
46 osteosclerotic myeloma 10.3 IL1B IL6 TNF
47 poems syndrome 10.3 IL1B IL6 TNF
48 primary peritoneal carcinoma 10.3 CXCL8 IFNG IL10
49 recurrent corneal erosion 10.3 CXCL8 IL1B IL6
50 hypersensitivity reaction type iv disease 10.3 IFNG TLR9 TNF

Graphical network of the top 20 diseases related to Trypanosomiasis:



Diseases related to Trypanosomiasis

Symptoms & Phenotypes for Trypanosomiasis

GenomeRNAi Phenotypes related to Trypanosomiasis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 ALB CALR CCL2 CCL3 CXCL8 IDO1

MGI Mouse Phenotypes related to Trypanosomiasis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.26 ALB CALR HP IDO1 IFNG IL10
2 homeostasis/metabolism MP:0005376 10.22 ALB CALR HP IDO1 IFNG IL10
3 hematopoietic system MP:0005397 10.17 HP IDO1 IFNG IL10 IL1B IL4
4 immune system MP:0005387 10.11 CCL2 HP IDO1 IFNG IL10 IL1B
5 mortality/aging MP:0010768 10.07 ALB CALR HP IFNG IL10 IL1B
6 digestive/alimentary MP:0005381 10.06 ALB IFNG IL10 IL4 IL6 TLR2
7 liver/biliary system MP:0005370 9.92 ALB HP IFNG IL10 IL4 IL6
8 muscle MP:0005369 9.76 ALB CALR IDO1 IFNG IL10 IL6
9 neoplasm MP:0002006 9.56 ALB HP IFNG IL10 IL1B IL6
10 renal/urinary system MP:0005367 9.23 ALB HP IDO1 IFNG IL4 IL6

Drugs & Therapeutics for Trypanosomiasis

Drugs for Trypanosomiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
2
Enalaprilat Approved Phase 4 76420-72-9 6917719
3
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
4
Warfarin Approved Phase 4 81-81-2 6691 54678486
5
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
6
Ornithine Approved, Nutraceutical Phase 4,Phase 3,Phase 2 3184-13-2, 70-26-8 6262
7 Nifurtimox Investigational Phase 4,Phase 3,Phase 2,Phase 1 23256-30-6
8
Coumarin Experimental Phase 4 91-64-5 323
9 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Immunologic Factors Phase 4,Phase 3,Phase 2,Not Applicable
13 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Not Applicable
14 Benzonidazole Phase 4,Phase 3,Phase 2,Not Applicable
15
protease inhibitors Phase 4
16 Adrenergic alpha-1 Receptor Antagonists Phase 4
17 Natriuretic Peptide, Brain Phase 4
18 Neurotransmitter Agents Phase 4,Phase 3
19 Antihypertensive Agents Phase 4,Phase 3
20 Adrenergic Antagonists Phase 4,Phase 3
21 Adrenergic alpha-Antagonists Phase 4
22 HIV Protease Inhibitors Phase 4
23 Adrenergic beta-Antagonists Phase 4,Phase 3
24 Adrenergic Agents Phase 4,Phase 3
25 Angiotensin-Converting Enzyme Inhibitors Phase 4
26 Vasodilator Agents Phase 4,Phase 3,Not Applicable
27 Anticoagulants Phase 4
28 Peripheral Nervous System Agents Phase 4,Phase 3
29 Analgesics, Non-Narcotic Phase 4
30 Analgesics Phase 4
31 Anti-Inflammatory Agents, Non-Steroidal Phase 4
32 Fibrinolytic Agents Phase 4
33 Antirheumatic Agents Phase 4,Phase 2
34 Cyclooxygenase Inhibitors Phase 4
35 Antipyretics Phase 4
36 Anti-Inflammatory Agents Phase 4
37 Platelet Aggregation Inhibitors Phase 4
38
Bisoprolol Approved Phase 3 66722-44-9 2405
39
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
40
Amiodarone Approved, Investigational Phase 3,Not Applicable 1951-25-3 2157
41
Coal tar Approved Phase 3 8007-45-2
42 Melarsoprol Investigational Phase 3 494-79-1
43 Sympatholytics Phase 3
44 Autonomic Agents Phase 3
45 Adrenergic beta-1 Receptor Antagonists Phase 3
46 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 2,Not Applicable
47 Micronutrients Phase 3
48 Antioxidants Phase 3
49 Protective Agents Phase 3
50 Trace Elements Phase 3

Interventional clinical trials:

(show top 50) (show all 80)
# Name Status NCT ID Phase Drugs
1 Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase Completed NCT00906880 Phase 4 Nifurtimox-Eflronithine Combination Treatment (NECT)
2 Population Pharmacokinetics in Benznidazole-treated Adults With Chronic With Chagas Disease Completed NCT01755403 Phase 4 Benznidazole
3 Optimization of PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease Completed NCT01678599 Phase 4 Benznidazole
4 Population Pharmacokinetics Study of Benznidazole in Children With Chagas'Disease Completed NCT01549236 Phase 4 Benznidazole 12,5mg or 100mg
5 Exercise Training in Chagas Cardiomyopathy Completed NCT01006473 Phase 4
6 A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy Completed NCT01557140 Phase 4 RASi plus carvedilol
7 Outcomes of an Anticoagulation Clinic in an University Hospital Completed NCT01006486 Phase 4
8 Clinical Assessment, Neuroimaging and Immunomarkers in Chagas Disease Study (CLINICS) Recruiting NCT01650792 Phase 4 Aspirin
9 Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease Terminated NCT01539161 Phase 4
10 Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study Unknown status NCT02169557 Phase 2, Phase 3 Fexinidazole
11 Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study Unknown status NCT02184689 Phase 2, Phase 3 fexinidazole
12 BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease Unknown status NCT00123916 Phase 3 Benznidazole;Placebo
13 Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis Completed NCT00146627 Phase 3 Eflornithine;Nifurtimox
14 Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2 Completed NCT01685827 Phase 2, Phase 3 Fexinidazole;Nifurtimox;Eflornithine
15 Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC Completed NCT01589289 Phase 3
16 Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial Completed NCT02386358 Phase 3 Benznidazole;Placebo
17 Physical Exercise Program in Chronic Chagas Heart Disease Completed NCT02517632 Phase 3
18 Cardiac Rehabilitation in Chagas Heart Failure Completed NCT02516293 Phase 2, Phase 3
19 Chagas Cardiomyopathy Bisoprolol Intervention Study: Charity Completed NCT00323973 Phase 3 Bisoprolol
20 Prospective Study on Efficacy and Safety of SCYX-7158 in Patients Infected by Human African Trypanosomiasis Due to T.b. Gambiense Recruiting NCT03087955 Phase 2, Phase 3 SCYX 7158
21 Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage Recruiting NCT03025789 Phase 3 Fexinidazole
22 CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY) Recruiting NCT02369978 Phase 2, Phase 3 Nifurtimox;Benznidazole;Placebo
23 Selenium Treatment and Chagasic Cardiopathy (STCC) Recruiting NCT00875173 Phase 3 Selenium;Placebo (for Selenium)
24 A Trial Testing Amiodarone in Chagas Cardiomiopathy Recruiting NCT03193749 Phase 3 Amiodarone Hydrochloride;Placebo Oral Tablet
25 Prospective Study of a Pediatric Nifurtimox Formulation for Chagas' Disease Active, not recruiting NCT02625974 Phase 3 Nifurtimox (BAYA2502);Nifurtimox (BAYA2502) followed by Placebo
26 Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age Not yet recruiting NCT03672487 Phase 3 Benznidazole;Placebo Oral Tablet
27 Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda Terminated NCT00489658 Phase 2, Phase 3 Eflornithine plus Nifurtimox combination therapy
28 Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis Terminated NCT00330148 Phase 3 melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d;melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d;nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d
29 Cell Therapy in Chagas Cardiomyopathy Terminated NCT00349271 Phase 3 Filgrastime (G-CSF);Standart therapy
30 Study to Evaluate Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chagas Disease Unknown status NCT02498782 Phase 2 Fexinidazole;Placebo
31 Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease Unknown status NCT01489228 Phase 2 E1224;Benznidazole;Placebo
32 Trial of DB289 for the Treatment of Stage I African Trypanosomiasis Completed NCT00803933 Phase 2 DB289;Pentamidine
33 A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis Completed NCT00802594 Phase 2 DB289
34 A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267) Completed NCT01377480 Phase 2 Posaconazole;Placebo for posaconazole;Benznidazole
35 Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole Completed NCT01162967 Phase 2 Benznidazole;Posaconazole
36 Oral Fexinidazole Dosing Regimens for the Treatment of Adults With Chronic Indeterminate Chagas Disease Recruiting NCT03587766 Phase 2 Fexinidazole;Placebo Oral Tablet
37 Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease. Recruiting NCT03191162 Phase 2 Benznidazole
38 Colchicine for Patients With Chagas´ Disease( B1 Stage) Active, not recruiting NCT03704181 Phase 2 Colchicine 0.5 MG twice day for one year;Placebo Oral Tablet
39 BENDITA BEnznidazole New Doses Improved Treatment and Associations Active, not recruiting NCT03378661 Phase 2 Benznidazole;E1224;E1224 Placebo;Benznidazole Placebo
40 Evaluation of G-CSF (Colony Stimulating Factor) in Patients With Chronic Chagas Cardiomyopathy Enrolling by invitation NCT02154269 Phase 2 Treatment with G-CSF (Granulocyte colony stimulating factor);Placebo saline
41 Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the Fexinidazole Completed NCT00982904 Phase 1 Fexinidazole/Placebo
42 Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158 Completed NCT01533961 Phase 1 SCYX-7158;Placebo
43 Bioequivalence Study - Reference Clinical Fexinidazole Tablet Versus Proposed Market Formulation Completed NCT02571062 Phase 1 Fexinidazole
44 Fexinidazole (1200mg) Bioavailability Under Different Food Intake Conditions Completed NCT01340157 Phase 1 Fexinidazole
45 Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg Completed NCT03350295 Phase 1 Nifurtimox (Lampit, BAYA2502)
46 Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients Completed NCT02606864 Phase 1 Nifurtimox (BAYa2502)
47 Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients Completed NCT01927224 Phase 1 Nifurtimox (BAYa2502) (4 x 30 mg tablet);Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water);Nifurtimox (BAYa2502) (120 mg tablet)
48 Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study Not yet recruiting NCT03334838 Phase 1 Nifurtimox (Lampit, BAYA2502)
49 Multiple Dose Study to Evaluate Security, Tolerance and Pharmacokinetic of Fexinidazole (Drug Candidate for Human African Trypanosomiasis) Administered With a Loading Dose and With Food Terminated NCT01483170 Phase 1 Tablets Fexinidazole;Placebo
50 Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram Unknown status NCT00453700 Not Applicable

Search NIH Clinical Center for Trypanosomiasis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: trypanosomiasis

Genetic Tests for Trypanosomiasis

Anatomical Context for Trypanosomiasis

MalaCards organs/tissues related to Trypanosomiasis:

41
Testes, Brain, T Cells, Heart, B Cells, Kidney, Lung

Publications for Trypanosomiasis

Articles related to Trypanosomiasis:

(show top 50) (show all 1279)
# Title Authors Year
1
Melarsoprol Resistance in African Trypanosomiasis. ( 29705579 )
2018
2
Integrated cost-benefit analysis of tsetse control and herd productivity to inform control programs for animal African trypanosomiasis. ( 29514668 )
2018
3
A case of delayed diagnosis of East-African trypanosomiasis in a Dutch traveller. ( 29688491 )
2018
4
No evidence for association between APOL1 kidney disease risk alleles and Human African Trypanosomiasis in two Ugandan populations. ( 29470556 )
2018
5
Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo. ( 29897919 )
2018
6
African Trypanosomiasis-Associated Anemia: The Contribution of the Interplay between Parasites and the Mononuclear Phagocyte System. ( 29497418 )
2018
7
Brain-penetrant, triazolopyrimidine and phenylpyrimidine microtubule-stabilizers as potential leads to treat human African trypanosomiasis. ( 29969537 )
2018
8
FDG PET/CT in a Case of Human African Trypanosomiasis (Sleeping Sickness). ( 29863573 )
2018
9
Trypanosomiasis in a Young Infant from Rural Gujarat, India. ( 29396940 )
2018
10
Oral fexinidazole for human African trypanosomiasis. ( 29353603 )
2018
11
The impact of passive case detection on the transmission dynamics of gambiense Human African Trypanosomiasis. ( 29624584 )
2018
12
A Phase III Diagnostic Accuracy Study of a Rapid Diagnostic Test for Diagnosis of Second-Stage Human African Trypanosomiasis in the Democratic Republic of the Congo. ( 29246478 )
2018
13
Identification of a 4-fluorobenzyl l-valinate amide benzoxaborole (AN11736) as a potential development candidate for the treatment of Animal African Trypanosomiasis (AAT). ( 29169674 )
2018
14
Compounds from African Medicinal Plants with Activities Against Selected Parasitic Diseases: Schistosomiasis, Trypanosomiasis and Leishmaniasis. ( 29744736 )
2018
15
Human African trypanosomiasis: How do the parasites enter and cause dysfunctions of the nervous system in murine models? ( 29870779 )
2018
16
Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides. ( 29191556 )
2018
17
Current and Future Prospects of Nitro-compounds as Drugs for Trypanosomiasis and Leishmaniasis. ( 29701144 )
2018
18
A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda. ( 29471865 )
2018
19
Human African Trypanosomiasis in Emigrant Returning to China from Gabon, 2017. ( 29350158 )
2018
20
Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease. ( 29534061 )
2018
21
A meta-analysis of the prevalence of African animal trypanosomiasis in Nigeria from 1960 to 2017. ( 29720251 )
2018
22
The development of high resolution maps of tsetse abundance to guide interventions against human African trypanosomiasis in northern Uganda. ( 29884213 )
2018
23
The structure of serum resistance-associated protein and its implications for human African trypanosomiasis. ( 29358741 )
2018
24
Thiazole, thio and semicarbazone derivatives against tropical infective diseases: Chagas disease, human African trypanosomiasis (HAT), leishmaniasis, and malaria. ( 30453246 )
2018
25
Applying Loop-mediated Isothermal Amplification (LAMP) in the Diagnosis of Malaria, Leishmaniasis and Trypanosomiasis as Point-of-Care Tests (POCTs). ( 30360713 )
2018
26
Advanced in silico methods for the development of anti-leishmaniasis and anti-trypanosomiasis agents. ( 30378482 )
2018
27
Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. ( 29113731 )
2018
28
Parasitological and Molecular Detection of Canine Trypanosomiasis From Riyadh Province, Saudi Arabia. ( 29990441 )
2018
29
Integrating innovations: a qualitative analysis of referral non-completion among rapid diagnostic test-positive patients in Uganda's human African trypanosomiasis elimination programme. ( 30119700 )
2018
30
Clinical management of East African trypanosomiasis in South Africa: Lessons learned. ( 30153486 )
2018
31
The activity of Artemisia spp. and their constituents against Trypanosomiasis. ( 30166103 )
2018
32
A systematic review and meta-analysis of small ruminant and porcine trypanosomiasis prevalence in sub-Saharan Africa (1986 to 2018). ( 30179607 )
2018
33
The Long Wait for a New Drug for Human African Trypanosomiasis. ( 30181071 )
2018
34
Molecular detection of equine trypanosomiasis in the Riyadh Province of Saudi Arabia. ( 30204053 )
2018
35
Innovative digital technologies for quality assurance of diagnosis of human African trypanosomiasis. ( 30212459 )
2018
36
Cost-effectiveness of using a rapid diagnostic test to screen for human African trypanosomiasis in the Democratic Republic of the Congo. ( 30240406 )
2018
37
Knowledge, attitudes and practices about human African trypanosomiasis and their implications in designing intervention strategies for Yei county, South Sudan. ( 30273342 )
2018
38
Climate change and African trypanosomiasis vector populations in Zimbabwe's Zambezi Valley: A mathematical modelling study. ( 30346952 )
2018
39
A meta-analysis of the prevalence of bovine trypanosomiasis in some African countries from 2000 to 2018. ( 30388996 )
2018
40
Exploring the effect of human and animal population growth on vector-borne disease transmission with an agent-based model of Rhodesian human African trypanosomiasis in eastern province, Zambia. ( 30408045 )
2018
41
Human African trypanosomiasis caused by Trypanosoma brucei gambiense: The first case report in China. ( 30423460 )
2018
42
The elimination of human African trypanosomiasis is in sight: Report from the third WHO stakeholders meeting on elimination of gambiense human African trypanosomiasis. ( 30521522 )
2018
43
Monitoring the elimination of human African trypanosomiasis: Update to 2016. ( 30521525 )
2018
44
Pastoralists' Vulnerability to Trypanosomiasis in Maasai Steppe. ( 29098491 )
2017
45
Bovine trypanosomiasis in tsetse-free pastoral zone of the Far-North region, Cameroon. ( 29097642 )
2017
46
Performance of the SD BIOLINEAr HAT rapid test in various diagnostic algorithms for gambiense human African trypanosomiasis in the Democratic Republic of the Congo. ( 28672036 )
2017
47
Sexual transmission of American trypanosomiasis in humans: a new potential pandemic route for Chagas parasites. ( 28591404 )
2017
48
Use of Zymography in Trypanosomiasis Studies. ( 28608214 )
2017
49
Human African trypanosomiasis control: Achievements and challenges. ( 28426685 )
2017
50
Case of Nigeria-Acquired Human African Trypanosomiasis in United Kingdom, 2016. ( 28628444 )
2017

Variations for Trypanosomiasis

Expression for Trypanosomiasis

Search GEO for disease gene expression data for Trypanosomiasis.

Pathways for Trypanosomiasis

Pathways related to Trypanosomiasis according to GeneCards Suite gene sharing:

(show top 50) (show all 76)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.13 CALR CCL2 CCL3 CXCL8 HP IFNG
2
Show member pathways
13.74 CCL2 CCL3 CXCL8 IFNG IL10 IL1B
3
Show member pathways
13.63 CCL2 CCL3 CXCL8 IFNG IL10 IL1B
4
Show member pathways
13.54 CCL2 CCL3 CXCL8 IL10 IL1B IL4
5
Show member pathways
13.47 CCL2 CCL3 CXCL8 IFNG IL10 IL1B
6
Show member pathways
13.39 CCL2 CCL3 CXCL8 IL10 IL1B IL4
7
Show member pathways
13.18 CALR CCL2 CCL3 CXCL8 IL1B IL6
8
Show member pathways
13.09 CALR CCL2 CCL3 CXCL8 IFNG IL10
9
Show member pathways
13.02 CALR CXCL8 IFNG IL10 IL1B IL4
10
Show member pathways
12.93 CCL2 CXCL8 IFNG IL1B IL4 IL6
11
Show member pathways
12.81 CXCL8 IFNG IL1B IL6 TNF
12
Show member pathways
12.77 IL1B IL6 TLR2 TLR9 TNF
13
Show member pathways
12.75 IFNG IL10 IL1B IL4 IL6 TLR2
14
Show member pathways
12.71 CCL2 IFNG IL10 IL1B IL6 TNF
15 12.68 CCL2 IDO1 IFNG IL10 IL1B IL4
16
Show member pathways
12.58 IFNG IL10 IL1B IL4 IL6 TNF
17
Show member pathways
12.49 ALB CCL2 IFNG IL1B IL4 IL6
18
Show member pathways
12.47 CCL2 CXCL8 IFNG IL1B IL4 IL6
19
Show member pathways
12.42 CXCL8 IFNG IL1B IL6 TNF
20
Show member pathways
12.42 IFNG IL10 IL1B IL4 TLR2 TNF
21
Show member pathways
12.42 CXCL8 IFNG IL10 IL1B IL4 IL6
22 12.4 IFNG IL10 IL1B IL6 TLR2 TLR9
23
Show member pathways
12.39 CXCL8 IL6 TLR2 TLR9 TNF
24 12.35 CALR IL6 TLR2 TNF
25
Show member pathways
12.35 CXCL8 IL1B IL6 TLR2 TNF
26
Show member pathways
12.34 IL10 IL1B IL6 TLR9 TNF
27 12.34 CXCL8 IL10 IL1B IL6 TF TNF
28
Show member pathways
12.32 CCL2 CCL3 CXCL8 IL1B TLR2 TLR9
29 12.32 IFNG IL6 TLR2 TLR9 TNF
30
Show member pathways
12.25 CXCL8 IFNG IL1B IL4 IL6 TLR2
31
Show member pathways
12.22 CCL2 CCL3 CXCL8 IFNG IL10 IL1B
32
Show member pathways
12.22 IFNG IL10 IL1B IL6 TLR2 TLR9
33
Show member pathways
12.21 IFNG IL1B IL4 IL6 TLR2 TNF
34 12.18 CCL2 IFNG IL1B TNF
35 12.17 CCL2 CXCL8 IFNG IL1B IL4 IL6
36 12.16 IFNG IL10 IL4 IL6 TNF
37 12.12 CCL2 CXCL8 IL10 IL1B IL4 IL6
38 12.11 CCL3 CXCL8 IFNG IL1B IL6
39
Show member pathways
12.1 ALB APOL1 CALR HP HPR
40
Show member pathways
12.08 CCL3 IFNG IL1B IL4
41 12.07 CCL2 IL1B IL6 TNF
42 12.07 CCL2 CXCL8 IL1B IL6 TNF
43 12.01 IL1B IL4 IL6 TNF
44 12 CCL3 CXCL8 IFNG IL1B IL6
45 11.98 CXCL8 IFNG IL10 IL1B IL6 TLR2
46 11.96 CCL3 IFNG IL10 IL1B IL4 TNF
47 11.93 CXCL8 IFNG IL4 IL6
48 11.93 CXCL8 IL10 IL1B IL6 TNF
49 11.91 IFNG IL10 IL1B IL6 TLR9 TNF
50
Show member pathways
11.9 CXCL8 IFNG IL4 TNF

GO Terms for Trypanosomiasis

Cellular components related to Trypanosomiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 ALB APOL1 CALR CCL2 CCL3 CXCL8
2 endoplasmic reticulum lumen GO:0005788 9.65 ALB APOL1 CALR IL6 TF
3 blood microparticle GO:0072562 9.55 ALB APOL1 HP HPR TF
4 extracellular space GO:0005615 9.5 ALB APOL1 CALR CCL2 CCL3 CXCL8

Biological processes related to Trypanosomiasis according to GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Name GO ID Score Top Affiliating Genes
1 cellular response to lipopolysaccharide GO:0071222 9.99 CCL2 CXCL8 IL10 IL1B IL6 TNF
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.97 IL1B IL6 TLR2 TLR9 TNF
3 positive regulation of DNA-binding transcription factor activity GO:0051091 9.96 IL10 IL1B IL6 TNF
4 response to organic substance GO:0010033 9.95 CALR HP HPR IL10 TNF
5 neutrophil chemotaxis GO:0030593 9.94 CCL2 CCL3 CXCL8 IL1B
6 positive regulation of inflammatory response GO:0050729 9.93 CCL3 TLR2 TLR9 TNF
7 positive regulation of JNK cascade GO:0046330 9.92 IL1B TLR9 TNF
8 cellular response to interleukin-1 GO:0071347 9.92 CCL2 CCL3 CXCL8
9 cytokine-mediated signaling pathway GO:0019221 9.92 CCL2 CCL3 CXCL8 IL10 IL1B IL4
10 chemokine-mediated signaling pathway GO:0070098 9.91 CCL2 CCL3 CXCL8
11 cellular response to organic cyclic compound GO:0071407 9.91 CCL2 CCL3 IL1B TNF
12 response to glucocorticoid GO:0051384 9.91 IL10 IL1B IL6 TNF
13 regulation of signaling receptor activity GO:0010469 9.91 CCL2 CCL3 CXCL8 IFNG IL10 IL1B
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.9 IFNG IL4 IL6
15 regulation of insulin secretion GO:0050796 9.9 IFNG IL1B TNF
16 positive regulation of T cell proliferation GO:0042102 9.89 IL1B IL4 IL6
17 positive regulation of tumor necrosis factor production GO:0032760 9.88 CCL3 TLR2 TLR9
18 humoral immune response GO:0006959 9.88 CCL2 IFNG IL6 TNF
19 protein kinase B signaling GO:0043491 9.87 CCL2 CCL3 IL1B TNF
20 monocyte chemotaxis GO:0002548 9.86 CCL2 CCL3 IL6
21 positive regulation of nitric oxide biosynthetic process GO:0045429 9.86 IFNG IL1B TNF
22 positive regulation of interleukin-6 production GO:0032755 9.85 IL1B IL6 TLR2 TLR9 TNF
23 positive regulation of JUN kinase activity GO:0043507 9.84 IL1B TLR9 TNF
24 positive regulation of phagocytosis GO:0050766 9.84 CALR IL1B TNF
25 positive regulation of interleukin-8 production GO:0032757 9.84 IL1B TLR2 TLR9 TNF
26 negative regulation of interleukin-6 production GO:0032715 9.83 IL10 TLR9 TNF
27 positive regulation of interleukin-12 production GO:0032735 9.83 IDO1 IFNG TLR2 TLR9
28 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.83 CALR IL1B TLR2 TLR9 TNF
29 negative regulation of neurogenesis GO:0050768 9.82 IL1B IL6 TNF
30 positive regulation of gene expression GO:0010628 9.81 CALR CCL3 IFNG IL1B IL4 IL6
31 positive regulation of glial cell proliferation GO:0060252 9.8 IL1B IL6 TNF
32 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.79 IFNG IL1B TNF
33 positive regulation of chemokine production GO:0032722 9.78 IL6 TLR2 TLR9 TNF
34 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.77 IL10 IL1B TNF
35 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.77 CCL2 TLR2 TLR9
36 lipopolysaccharide-mediated signaling pathway GO:0031663 9.77 CCL2 CCL3 IL1B TLR2 TNF
37 cell activation GO:0001775 9.75 CCL3 TLR2
38 I-kappaB phosphorylation GO:0007252 9.75 TLR2 TLR9
39 PERK-mediated unfolded protein response GO:0036499 9.75 CCL2 CXCL8
40 polyamine biosynthetic process GO:0006596 9.74 AMD1 ODC1
41 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.74 IL1B TLR9
42 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.74 TLR9 TNF
43 negative regulation of lipid storage GO:0010888 9.73 IL6 TNF
44 positive regulation of neuroinflammatory response GO:0150078 9.73 IL1B IL6 TNF
45 endothelial cell apoptotic process GO:0072577 9.72 IL10 TNF
46 polyamine metabolic process GO:0006595 9.72 AMD1 ODC1
47 positive regulation of chemokine biosynthetic process GO:0045080 9.72 IL1B TNF
48 negative regulation of interleukin-8 production GO:0032717 9.71 IL10 TLR9
49 positive regulation of MHC class II biosynthetic process GO:0045348 9.71 IL10 IL4
50 regulation of establishment of endothelial barrier GO:1903140 9.71 IL1B TNF

Molecular functions related to Trypanosomiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.33 CCL2 CCL3 CXCL8
2 cytokine activity GO:0005125 9.28 CCL2 CCL3 CXCL8 IFNG IL10 IL1B
3 signaling pattern recognition receptor activity GO:0008329 9.26 TLR2 TLR9
4 hemoglobin binding GO:0030492 8.96 HP HPR

Sources for Trypanosomiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....